

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON3		SERIAL NO.: Not yet known 10/056,475	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: Herewith		GROUP: Not Yet Known 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
[Signature]	AA	5 8 5 9 2 5 7	01/12/89	Talley	548	247	08/14/96
	AB	5 8 6 3 9 2 2	01/26/89	Mayer, et al.	514	270	07/02/99
	AC	5 8 4 0 7 3 1	11/24/88	Mayer, et al.	514	289	08/02/95
	AD	5 8 6 9 4 9 8	02/09/89	Mayer, et al.	514	282	07/07/97
	AE	5 8 6 1 4 1 9	07/19/89	Dube, et al.	514	334	07/11/97
	AF	5 7 8 9 4 1 3	08/04/88	Black, et al.	514	255	01/21/97
	AG	5 8 0 4 2 6 0	02/18/87	Gaey, et al.	514	605	11/04/93
	AH	5 4 5 8 8 7 9	10/17/95	Singh, et al.	424	400	09/30/94
	AI	5 5 1 6 8 0 3	05/14/96	Ralla	514	570	03/01/95
	AJ	5 8 4 3 4 6 8	12/01/88	Burkoth, et al.	424	448	05/13/96
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
[Signature]	AK	Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX-2) By NSAIDs: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Pairet, et al., <i>Inflammopharmacology</i> 4: 61-70, (1998).					
	AL	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. <i>European J. Pharm</i> 355 pp 211-217, (1998).					
	AM	Cyclooxygenases 1 and 2, J.R. Vane, et al. <i>Annu. Rev. Pharmacol. Toxicol.</i> 38: 87-121, (1998).					
	AN	Analysis of the effects of cyclooxygenase (COX) 1 and COX 2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. <i>Brain Research</i> 738:104-110, (1999).					
	AO	Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., <i>Skin Pharmacol. And Applied Skin Phys.</i> 11:273-278, (1998).					
	AP	Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Carthaya Hay and Jacqueline de Belleroche, <i>Neuro Report</i> 8, 1248-1251, (1997).					
	AQ	The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, <i>Drugs</i> 52 Supp. 5:13-23, (1996).					
	AR	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. <i>Inflamm. Res.</i> 47:79-85, (1998).					
AS	Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Dan E. Griswold and Jerry L. Adams, <i>Medicinal Research Reviews</i> , Vol. 16, No. 2, pp. 181-206, (1996).						
EXAMINER [Signature]				DATE CONSIDERED 8/26/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

U.S. PATENT  
10/056475  
07/25/03

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1079CON3

SERIAL NO.: Not Yet Known

16/056,475

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known

1639

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA					
	BB					
	BC					
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					
	BJ					
	BK					

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
					YES NO
BL					

## OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, Etc.)

BM	Cyclooxygenase in biology and disease. Raymond N. Dubois, et al., FASEB J. Vol. 12 pp. 1063-1073 (1998).
BN	Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With An Improved Safety Profile Through Preferential Inhibition of COX-2. G. Engelhardt, British J. Rheumatology, 35 (supp 11):4-12, (1996)
BO	Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice, Implications for Gastrointestinal Toxicity. John L. Wallace, et al. Gastroenterology, 115:101-109 (1998).
BP	Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. M. Parrot and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15, (1996).
BQ	Involvement of Prostaglandins Produced by Cyclooxygenase 1 in Murine Visceroneuropathic Induced by Phenylquinone. Hidenobu Kusahara, et al. Prostaglandins 55: 43-49, (1998).
BR	Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats. D. Dring, et al. J. Pharmacol. And Experimental Therapeutics. Vol. 285, No. 3, pp 1031-1038.

EXAMINER

DATE CONSIDERED

16/05/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON3		SERIAL NO.: Not Yet Known <i>101056, 475</i>	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.		FILING DATE: Not Yet Known	
				GROUP: Not Yet Known <i>1639</i>			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						
	CC						
	CD						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
<i>[Signature]</i>	CE	9 9 0 7 4 1 3	2/18/99	WO			
	CF	9 9 3 2 1 1 9	7/1/99	WO			
	CG						
	CH						
	CI						
	CJ						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	CK	Effect of meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al, British Journal of Anaesthesia 84 (2) 151-4 (2000).					
	CL	Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats. C.S. Wong et al., British Journal of Anaesthesia 85 (5) 747-51 (2000).					
	CM	Cyclooxygenase inhibitors increase morphine effects on mesolimbic dopamine neurons. M. Melis, et al. Eur. J. Pharmacology 387 (1) R1-R3 (2000).					
	CN	Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX-1 and COX-2 inhibitors in nerve-injured rats, J.M. Lashbrook, et al. Pain 82 (1) 65-72 (1999).					
<i>[Signature]</i>	CO	Enhancement of opioid inhibition of gaba-ergic synaptic transmission by cyclooxygenase inhibitors in rat periaqueductal grey neurones, Vaughn et al. British Journal of Pharmacology 123 (8) 1479-81 (1998).					
EXAMINER <i>[Signature]</i>				DATE CONSIDERED <i>8/26/04</i>			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON3		SERIAL NO.: Not Yet Known <u>10/056,475</u>	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.		FILING DATE: Not Yet Known	
						GROUP: Not Yet Known <u>1639</u>	

  

U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	DOC	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5	4	7	4	9	9	5						
	DB	5	4	7	4	9	9	5	12/12/85	Ducharme et al.	514	241	01/10/94	
	DB	5	4	7	4	9	9	5	11/25/97	Black et al.	514	473	05/18/95	
	DC													
	DD													
	DE													
	DF													
	DG													
	DH													
	DI													
	DJ													
DK														

  

FOREIGN PATENT DOCUMENTS																	
DOC	DOC	DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
		5	4	7	4	9	9	5								YES	NO
DL																	
DM																	
DN																	
DO																	
DP																	

  

OTHER PRIOR ART (Including Author, Title, Date, Portent Pages, Etc.)												
DOC												
DR												
DS												

  

EXAMINER	DATE CONSIDERED <u>5/20/04</u>
----------	--------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079C003		SERIAL NO.: Not Yet Known <i>10/056,475</i>	
LIST OF PRIOR ART CITED BY APPLICANT  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: Not Yet Known		GROUP: Not Yet Known <i>1a 89</i>	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>[Handwritten Initials]</i>	EA	3 8 0 0 0 4 1	03/28/74	Miller, et al.	424	273	03/02/71
	EB	4 3 2 2 4 2 7	03/30/82	Boyinski, et al.	424	260	04/16/81
	EC	4 3 3 8 3 2 4	06/06/82	Gardocki	424	266	03/17/81
	ED	4 4 0 4 2 1 0	09/13/83	Schmidt	424	260	06/30/82
	EE	4 4 0 7 8 0 4	10/04/83	Schmidt	424	260	06/30/82
	EF	4 4 0 7 8 0 5	10/04/83	Schmidt	424	260	08/30/82
	EG	4 4 6 4 3 7 6	08/07/84	Sunshine, et al.	424	253	10/11/83
<i>[Handwritten Initials]</i>	EH	4 4 8 6 4 3 6	12/04/84	Sunshine, et al.	424	253	03/11/83
	EI	4 4 8 9 0 8 0	12/18/84	Loren	424	260	12/06/82
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
<i>[Handwritten Initials]</i>	EJ	2 0 2 3 3 4 9	02/18/91	Canada	A61K	31/44	<i>[Handwritten Mark]</i>
	EK	0 2 7 4 8 4 5	07/20/88	EP (A1)	A61K	31/19	<i>[Handwritten Mark]</i>
	EL	0 3 8 8 1 2 5	09/19/90	EP (A1)	A61K	31/485	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
<i>[Handwritten Initials]</i>	EM	Pharmacokinetics and Drug Input Characteristics for a Diclofenac/Codine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. Arzneimittel-Forsch./Drug Res. 46 (II) 57-63 (1996).					
	EN	Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codine Combination in Chronic Osteo-arthritis G.K. Vlok, et al. Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg. pp 36, (1987).					
	EO						
	EP						
	EQ						
ER							
EXAMINER <i>[Handwritten Signature]</i>				DATE CONSIDERED <i>8/26/04</i>			

\*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 603; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 200.1078CON3

SERIAL NO.: Not Yet Known  
10/05/84 475

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: Not Yet Known

GROUP: Not Yet Known  
639

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MM	FA	4 5 6 7 1 8 3	01/28/86	Sunshine, et al.	514	264	12/12/83
	FB	4 5 6 9 9 3 7	02/11/86	Baker, et al.	514	282	02/11/83
	FC	4 5 7 1 4 0 0	02/18/86	Arnold	514	282	12/18/84
	FD	4 5 8 7 2 5 2	05/06/86	Arnold	514	282	12/18/84
	FE	4 6 1 9 9 3 4	12/28/86	Sunshine, et al.	514	277	07/08/85
	FF	4 6 9 0 9 2 7	09/01/87	Voss, et al.	514	282	02/03/86
	FG	4 8 3 9 1 7 6	06/13/89	Palikhanis, et al.	424	465	12/06/87
	FH	4 8 4 4 9 0 7	07/04/89	Elger, et al.	424	465	08/14/86
	FI	4 9 2 7 8 5 4	05/22/90	Sunshine, et al.	514	570	08/21/89
	FJ	5 1 6 4 3 9 8	12/17/82	Sims, et al.	514	282	04/01/91
	FK	5 1 9 0 9 4 7	03/02/93	Riess, et al.	514	282	08/16/91
MM	FL	5 2 4 0 6 9 4	08/31/93	Gwaltney, Jr.	424	45	12/19/91

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
MM	FM	0 0 6 8 8 3 8	06/25/82	EP (A1)	A61K	31/485		
	FN	0 0 6 8 8 3 8	06/25/82	EP (B1)	A61K	31/485		
MM	FO	2 0 8 1 6 0 4	05/01/95	Canada	A61K	03/1135		
	FP							
	FO							

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FR	
FS	
FT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1078CDN3		SERIAL NO.: Not Yet Known <i>101056, 471</i>								
<b>LIST OF PRIOR ART CITED BY APPLICANT</b>  (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.		GROUP: Not Yet Known <i>1639</i>								
				FILING DATE: Not Yet Known										
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<i>DA</i>	GA	5	4	0	9	9	4	4	04/25/95	Black, et al.	514	359	03/12/93	
	GB	5	4	3	6	2	6	5	06/25/95	Black, et al.	514	420	11/12/93	
	GC	5	5	1	0	3	6	8	04/23/96	Lau, et al.	514	419	05/22/95	
	GD	5	5	2	1	2	1	3	05/28/96	Prasit, et al.	514	443	08/28/94	
	GE	5	5	5	0	1	4	2	08/27/96	Ducharme et al.	514	365	05/08/95	
	GF	5	5	5	2	4	2	2	09/03/96	Gauthier, et al.	514	368	01/11/95	
<i>DA</i>	GG	5	6	0	4	2	5	3	02/18/97	Lau, et al.	514	415	05/22/95	
	GH	5	6	3	9	7	8	0	06/17/97	Lau, et al.	514	419	05/22/95	
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	GI													
	GJ													
	GK													
	GL													
	GM													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
<i>DA</i>	GN	Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Res. 47, Supplement 2 (1998).												
	GO													
	GP													
	GO													
	GR													
EXAMINER <i>[Signature]</i>										DATE CONSIDERED <i>8/26/04</i>				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPFP 605; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														





LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:  
September 17, 1998

GROUP: 1627  
639

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
													YES	NO
AA	0	6	5	4	2	6	3	05/24/95	EP (A1)	A61K	31/135			
AB	0	6	5	4	2	6	3	05/24/95	EP (B1)	A61K	31/135			
AC	9	7	1	7	9	7	8	05/22/97	WO	A61K	33/00			
AD	9	7	2	5	9	8	8	07/24/97	WO	A61K	31/495			
AE	9	7	3	2	8	5	7	09/12/97	WO	C07D	24/104			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Dray et al. New Pharmacological Strategies for Pain Relief. <u>Annual Review of Pharmacology &amp; Toxicology</u> , 36, pp. 253-280. (1996).
AG	Brasseur, L. Revue des therapeutiques pharmacologiques actuelles de la douleur. <u>Drugs</u> , 53 Suppl 2, pp. 10-17. (1997)
AH	Rang et al. New molecules in analgesia. <u>British Journal of Anesthesia</u> , 75, pp. 145-156 (1995)
AI	Beaver, WT. Combination Analgesics. <u>American Journal of Medicine</u> , 77 (Suppl 3A), pp. 38-53. (1984).
AJ	Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In <u>Evaluation and Treatment of Chronic Pain</u> , 2 <sup>nd</sup> ed., William & Wilkins pp. 363-383. (1992).
AK	Goodman & Gilman's. <u>The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Edition. McGraw-Hill, New York, pp 535 and 551-552.
AL	Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. <u>Pain</u> , 73, 3 pp. 401-406. (1997)
AM	Etches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. <u>Anesthesia &amp; Analgesia</u> , 81 (6), pp. 1175-1180. (1995).
AN	Hodsmann et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. <u>Anaesthesia</u> , 42(9), pp. 1005-1008. (1987).
AO	Kaasalainen et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. <u>Pain</u> , 70, 2-3, pp. 175-183. (1997).
AP	Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. <u>Journal of Clinical Pharmacology</u> , 37 (10), pp. 908-915. (1997).
AQ	Insel. Chapter 27: Analgesic-Antipyretic and Anti-Inflammatory Agents. In Hardman, ed., <u>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</u> , 9 <sup>th</sup> Edition. McGraw-Hill, New York, pp. 654-655. (1996).
AR	Pollson. Non-steroidal Anti-inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. <u>The American Journal of Medicine</u> , 100 (Suppl 2A), pp. 2A-31S - 2A-36S. (1996).
AS	Vane, J. Towards a better aspirin. <u>Nature</u> , 367, pp. 215-216. (1994).
AT	Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX 'Selectivity'. <u>Journal of Clinical Rheumatology</u> , 2 (3), pp. 135-140. (1996).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10/05/97

## LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE: September  
17, 1998

GROUP: 1627

1639

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

- BA Van Ryn et al. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. Expert Opinion On Investigational Drugs, pp. 609-614. (1997).
- BB Vane et al. New insights into the mode of action of anti-inflammatory drugs. Inflammation Research, 44, (No.1), pp 1-10 (1995).
- BC Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. British Journal of Rheumatology, 34, Abstract Suppl. 1, p. 48. (1995). Abstract.
- BD Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. Journal of Rheumatology, Vol. 24, Suppl 48, pp. 20-24. (1997).
- BE Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration in Rats. Neuropharmacology Vol. 33, pp. 1609-1611. (1994).
- BF Donnelly et al. COX-II Inhibitors - a new generation of safer NSAIDs? Alimentary Pharmacology and Therapeutics, 11, 2, pp. 227-235. (1997).
- BG Wallace, J.L. Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. Gastroenterology, 112, 3, pp. 1000-1016. (1997).
- BH Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. J Rheumatology, 24, Suppl. 47, pp. 32-39. (1997).
- BI Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDs in Musculoskeletal Disease: A Canadian Consensus. Canadian Medical Association Journal, 155, 1, pp. 77-88. (1996).
- BJ Mehlisch et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. Journal of Clinical Pharmacology, 37, 9, 863. (1997). Abstract.
- BK Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointestinal Toxicity. Gut, 39, Suppl. 3, A151. (1996). Abstract.
- BL Penning et al. Synthesis and Biological Evaluation of the 1, 5 -diarylpyrazole class of cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). Journal Of Medicinal Chemistry, 40(9), 1347-65. (1997).
- BM Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. Journal Of Rheumatology, 24 Suppl 49, pp. 9-14. (1997).
- BN
- BO
- BP
- BQ
- BR
- BS
- BT

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449  
(REV. 7-80)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:  
200.1079US

SERIAL NO.:  
09154.354 101054.475

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:  
September 17, 1998

GROUP:  
1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>MM</i>	AH	0 7 3 4 2 7 5	11/04/1997	Australia	C07D	261/08		
	AI							
	AJ							
	AK							
	AL							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER

*MM*

DATE CONSIDERED

8/24/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.